Published • loading... • Updated
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Updated data showed 86.4% response and 100% disease control in the 3→1.5 mg/kg group, supporting further testing against pembrolizumab plus chemotherapy.
- On Thursday, Innovent Biologics announced preliminary clinical study results for IBI363, a first-in-class PD-1/IL-2α-bias bispecific fusion protein, at the 2026 American Society of Clinical Oncology Annual Meeting.
- IBI363 targets the PD-1/PD-L1 pathway while selectively activating the IL-2 pathway to ignite immunity, aiming to overcome resistance in patients with advanced non-small cell lung cancer .
- The study reports an 86.4% objective response rate in the 3×1.5 mg/kg dose group, with grade ≥3 treatment-related adverse events occurring in 65.2% of patients receiving this regimen.
- Innovent identified 3×1.5 mg/kg as the recommended dose, launching a randomized head-to-head trial comparing this regimen against pembrolizumab for first-line treatment of advanced NSCLC.
- Under a 2025 license agreement with Takeda Pharmaceutical Company Limited, Innovent will co-develop the drug globally while Takeda exclusively commercializes it outside the United States and China.
Insights by Ground AI
24 Articles
24 Articles
The Billings Gazette+23 Reposted by 23 other sources
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left1Leaning Right0Center16Last UpdatedBias Distribution94% Center
Bias Distribution
- 94% of the sources are Center
94% Center
C 94%
Factuality
To view factuality data please Upgrade to Premium
